CFM
DYN icon

Compass Financial Management’s Dyne Therapeutics DYN Stock Holding History

Compass Financial Management’s Portfolio DYN Stock Details DYN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$17.5K Buy
+724
New +$13.5K ﹤0.01% 929

Other funds holding DYN

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Compass Financial Management's DYN Position: Q2 2026 in Review

Compass Financial Management opened a new position in Dyne Therapeutics (DYN) in Q2 2026: 724 shares worth $17.5K. The stake represents ﹤0.01% of the portfolio and ranks #929 among its holdings.

230 funds tracked by Wall St. Rank hold DYN as of Q2 2026.

  • Compass Financial Management held 724 shares of Dyne Therapeutics worth $17.5K as of Q2 2026.
  • Dyne Therapeutics was a new Compass Financial Management position in Q2 2026.
  • Dyne Therapeutics made up ﹤0.01% of Compass Financial Management's portfolio in Q2 2026, its #929 holding.
  • 230 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q2 2026.

Based on Compass Financial Management's 13F filing for Q2 2026, filed 12 Aug 2026.